Adjuvant Capecitabine in Triple Negative Breast Cancer After Neoadjuvant Therapy with Residual Disease

  • Failure to achieve pathologic complete response (pCR):
    • Is associated with poorer prognosis:
      • Particularly for triple negative breast cancer
  • In the CREATE-X trial:
    • 910 patients with HER2-negative residual invasive breast cancer after neoadjuvant chemotherapy were randomized to receive standard postsurgical treatment with capecitabine or control
    • Adjuvant capecitabine:
      • Resulted in improved disease-free survival and overall survival:
        • With the bulk of the benefit seen only in the patients with triple negative disease
          • Based on this study, adjuvant capecitabine can be considered for patients with triple negative breast cancer and residual disease after neoadjuvant chemotherapy


1. Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164-172.

2. Masuda N, Lee S-J, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant Capecitabine for breast cancer after preoperative chemotherapy. New Engl J Med. 2017;376(22):2147-2159.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s